hTERT DNA vaccine - Invectys

Drug Profile

hTERT DNA vaccine - Invectys

Alternative Names: hTERT DNA immunotherapy - Invectys; Human telomerase reverse transcriptase DNA vaccine - Invectys; INVAC-1

Latest Information Update: 17 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Invectys
  • Class Cancer vaccines; DNA vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Lymphoid leukaemia
  • No development reported Solid tumours

Most Recent Events

  • 25 Jul 2018 Phase-II clinical trials in Lymphoid leukaemia (Second-line therapy or greater) in USA (Intradermal) (NCT03265717)
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (Intradermal, Injection)
  • 19 Dec 2017 Invectys receives the US FDA approval to proceed with a phase II of INVAC 1, using PharmaJet needle-free injection system
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top